can hers still sell semaglutide Hims & shares fall after FDA says no longer in shortage Novo partners with Hims &

These differing mechanisms translate into very different clinical profiles, risk considerations, and patient populations

The pre-filled nature of the device means that patients do not need to reconstitute or prepare the medication before each use

Conclusion Zepbound and Retatrutide are both exciting developments in the world of weight loss medicine

The SURMOUNT trials reported alopecia as an adverse event in a small but notable percentage of participants

The ban provisionally runs until June 2024

If you are you a medical professional or patient who has been affected by the shortage of these medications, please tell us about your situation.